Work

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0191-5

Authors: Mark A. Dickson, Michael S. Gordon, Gerald Edelman, Johanna C. Bendell, Ragini R. Kudchadkar, Patricia M. LoRusso, Stuart H. Johnston, Douglas O. Clary, Gary K. Schwartz

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Pinnacle Oncology Hematology, Mary Crowley Cancer Research Center, Sarah Cannon, Emory University, Yale University, Exelixis (United States), Columbia University Irving Medical Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2090799628

FWCI: 1.343

Cites: 13

Cited by: 32

Related to: 10